Streetwise Live! Presents Algernon Pharmaceuticals on 01/27/2022. Learn More

Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Fund Triples Holding of Drug Repurposing Firm

Share on Stocktwits


The Quick Take

  • AlphaNorth Partners Fund more than tripled its position in Algernon Pharmaceuticals in December.
  • The fund bolstered its Algernon holding at the average purchase price of $4.61 per share, which indicated a "very compelling" $7.8 million valuation, AlphaNorth noted.
  • AlphaNorth noted that 2022 should be a catalyst-rich year for Algernon, with the:
    • Launch of a clinical trial evaluating the psychedelic compound DMT as a treatment for patients after a stroke.
    • Q2/22 data readout from Algernon's Phase 2 trial of Ifenprodil in idiopathic pulmonary fibrosis/chronic cough.
    • Advancement of additional drug candidates into the clinic this year.
  • Algernon is well cashed-up with more than $2 million on the balance sheet.
  • The 2021 return of AlphaNorth Partners Fund was about 22%, above the 7.3% return of the TSX Venture Exchange index.

Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW:FSE) repurposes and develops existing drugs as treatments for diseases.

This approach saves up to five years of preclinical research and multimillions in research and development costs.

AGN has caught the eye of PennyQueen, an investor and online community builder, who says she is "beyond excited" about the company, which she calls "brilliant." 

To learn more about Algernon and what other investors are saying about it, click here.

algernon pharmaceuticals



1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Algernon Pharmaceuticals Inc. Click here for important disclosures about sponsor fees. 

3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Algernon Pharmaceuticals Inc., a company mentioned in this article.

6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.



Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe